{"id":2670,"date":"2023-04-03T20:20:00","date_gmt":"2023-04-03T20:20:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/arsredovisning-2022\/"},"modified":"2023-04-03T20:20:00","modified_gmt":"2023-04-03T20:20:00","slug":"arsredovisning-2022","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/","title":{"rendered":"\u00c5rsredovisning 2022"},"content":{"rendered":"<div class=\"mfn-body\">\n<p>Idag publicerar XVIVO Perfusion AB (publ) sin \u00e5rsredovisning f\u00f6r 2022. \u00c5rsredovisningen bifogas detta pressmeddelande i pdf-format och i ESEF-format (European Single Electronic Format) och den finns \u00e4ven tillg\u00e4nglig p\u00e5 <a href=\"https:\/\/www.xvivoperfusion.com\/corporate\/financial-reports\/\" rel=\"noopener\" target=\"_blank\">https:\/\/www.xvivoperfusion.com\/corporate\/financial-reports\/<\/a>.<\/p>\n<p>En tryckt \u00e5rsredovisning kan best\u00e4llas per telefon: 031-788 21 50 eller per e-post: <a href=\"mailto:info@xvivogroup.com\" rel=\"noopener\" target=\"_blank\">info@xvivogroup.com<\/a>.<\/p>\n<p>G\u00f6teborg, 3 april 2023<br \/>XVIVO Perfusion AB (publ)<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-fb9cf3b124f9\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr\/>\n<p>Christoffer Rosenblad, VD, +46 73 519 21 59, e-post: christoffer.rosenblad@xvivogroup.com<br \/>Kristoffer\u00a0Nordstr\u00f6m,\u00a0CFO, +46 73 519 21 64, e-post:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-da5f5ee9f867\">\n<p><strong class=\"mfn-heading-1\">Om oss<\/strong><\/p>\n<hr\/>\n<p>XVIVO grundades 1998 och \u00e4r ett medicintekniskt f\u00f6retag dedikerat till att f\u00f6rl\u00e4nga livet f\u00f6r donerade organ s\u00e5 att transplantationsteam runt om i v\u00e4rlden kan r\u00e4dda fler liv. V\u00e5ra l\u00f6sningar g\u00f6r det m\u00f6jligt f\u00f6r ledande kliniker och forskare att t\u00e4nja p\u00e5 gr\u00e4nserna f\u00f6r transplantationsmedicin.\u00a0XVIVO har sitt huvudkontor i G\u00f6teborg och har kontor och forskningsanl\u00e4ggningar p\u00e5 tv\u00e5 kontinenter. Bolaget \u00e4r noterat p\u00e5 Nasdaq Stockholm\u00a0och handlas under symbolen XVIVO. Mer information finns att l\u00e4sa p\u00e5 hemsidan www.xvivogroup.com\/us<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-vpml\">\n<p><em>Denna information \u00e4r s\u00e5dan information som XVIVO Perfusion AB \u00e4r skyldigt att offentligg\u00f6ra enligt lagen om v\u00e4rdepappersmarknaden. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2023-04-03 22:20 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/bc411ada-f678-41cc-934d-23e7d0cc9970\/xvivo-perfusion-ab-publ-arsredovisning-2022.pdf\" rel=\"noopener\" target=\"_blank\">XVIVO Perfusion AB (publ) \u00c5rsredovisning 2022<\/a><br \/><a href=\"https:\/\/storage.mfn.se\/10aad780-e224-4f29-8cb3-07bf9d6a0c15\/549300G2464FYLS14B41-2022-12-31-sv.zip\" rel=\"noopener\" target=\"_blank\">549300G2464FYLS14B41-2022-12-31-sv<\/a><br \/><a href=\"https:\/\/storage.mfn.se\/df58a670-1333-43fc-963e-8596e6fa8d40\/549300g2464fyls14b41-2022-12-31-sv-zip-viewer.html\" rel=\"noopener\" target=\"_blank\">549300G2464FYLS14B41-2022-12-31-sv.zip-viewer<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Idag publicerar XVIVO Perfusion AB (publ) sin \u00e5rsredovisning f\u00f6r 2022. \u00c5rsredovisningen bifogas detta pressmeddelande i pdf-format och i ESEF-format (European&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2670","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-annual"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00c5rsredovisning 2022 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c5rsredovisning 2022 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Idag publicerar XVIVO Perfusion AB (publ) sin \u00e5rsredovisning f\u00f6r 2022. \u00c5rsredovisningen bifogas detta pressmeddelande i pdf-format och i ESEF-format (European...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2022\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2022\\\/\",\"name\":\"\u00c5rsredovisning 2022 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2023-04-03T20:20:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/arsredovisning-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c5rsredovisning 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c5rsredovisning 2022 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/","og_locale":"en_US","og_type":"article","og_title":"\u00c5rsredovisning 2022 - XVIVO","og_description":"Idag publicerar XVIVO Perfusion AB (publ) sin \u00e5rsredovisning f\u00f6r 2022. \u00c5rsredovisningen bifogas detta pressmeddelande i pdf-format och i ESEF-format (European...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/","name":"\u00c5rsredovisning 2022 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2023-04-03T20:20:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/arsredovisning-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"\u00c5rsredovisning 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}